PubRank

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)

Clinical Trial ID NCT00901901

PubWeight™ 20.45‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00901901

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011 2.85
2 HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011 2.10
3 The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2010 2.07
4 Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2012 1.57
5 Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012 1.55
6 Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010 1.31
7 Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013 1.23
8 Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012 1.10
9 Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015 1.05
10 Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci 2014 0.89
11 Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2016 0.83
12 Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013 0.83
13 Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010 0.79
14 Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res 2009 0.76
15 Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011 0.75
16 Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Sci Rep 2016 0.75
17 Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016 0.75
Next 100